Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 106   

Articles published

JNJ 101.82 +0.12 (0.12%)
price chart
How Are Medtech's Emerging Markets Faring?—Johnson & Johnson
"Look, I think what we would say overall is we continue to see let's say a slightly increasing positive trend. So we saw hospital admissions I believe up around 2%.
Why Isn't Johnson & Johnson Making More Acquisitions?
A massive and uncharacteristically high cash stockpile has Johnson & Johnson's (NYSE:JNJ) management discussing how best to spend its money.
4 Reasons Why Johnson & Johnson Exploded Higher Following Its Q4 Earnings Release
On Tuesday morning, healthcare conglomerate Johnson & Johnson (NYSE:JNJ) released its fourth-quarter earnings results, with the data looking more or less in-line with what we've seen in recent quarters (i.
Johnson & Johnson beats 4Q profit views despite lower sales  Business Insider
Johnson & Johnson (JNJ) Stake Boosted by Cape Cod Five Cents Savings Bank
Johnson & Johnson logo Cape Cod Five Cents Savings Bank boosted its stake in Johnson & Johnson (NYSE:JNJ) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
Johnson & Johnson (JNJ) Shares Sold by Cambridge Advisors Inc.  The Vista Voice
Campbell Newman Asset Management Reduces Stake in Johnson & Johnson (JNJ)  Intercooler Financial
What Johnson & Johnson's Restructuring Means
Motley Fool healthcare contributor Todd Campbell and healthcare analyst Kristine Harjes discuss Johnson & Johnson's (NYSE:JNJ) decision to restructure its multi-billion dollar medical device business. What is the company planning for the division, and ...
Johnson & Johnson's Newest Billion-Dollar Blockbuster
Johnson & Johnson (NYSE:JNJ) just reported its full-year results for 2015, and while revenue overall fell 5.7% from 2014, sales of its diabetes drug Invokana surged 123% to $1.3 billion.
Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks
Becoming overly complacent in your assumptions is one of the most dangerous things an investor can do. This is why I like to start each year with a cold-hearted look at my core holdings to see if I can do better.
Healthcare Intelligence: Johnson & Johnson Is Finally In The Hotseat
Johnson & Johnson (NYSE:JNJ) is the leading health conglomerate we can learn from. Investors should always observe industry leaders to understand the market's pros and cons.
Johnson & Johnson Proposes a "Fat Tax" On Businesses
If today were April 1st, you'd think what you are about to read was completely made up. Unfortunately quite the opposite is true.
One Big Threat to Johnson & Johnson's Future
In this video segment, Motley Fool healthcare contributor Todd Campbell and healthcare analyst Kristine Harjes discuss the looming biosimilar threat to Johnson & Johnson's multi-billion dollar autoimmune disease drug and why investors shouldn't worry ...